• Catalyst filed an amendment to its Form 8-K to correct a scrivener’s error in the signature date of its previously filed report.
• The amendment states no other changes were made to the earlier Form 8-K.
• The filing also reports a New Jersey district court order delaying the bench trial with Hetero USA from March 23, 2026 to May 18, 2026.
• The trial concerns the validity of Catalyst’s Orange Book-listed Firdapse patents expiring in 2032, 2034, and 2037.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-114764), on March 19, 2026, and is solely responsible for the information contained therein.